HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Rapidly progressive glomerulonephritis — Clinical Guidelines

Overview

Rapidly progressive glomerulonephritis (RPGN) is characterized by a rapid decline in renal function, often presenting with nephritic syndrome, and encompasses three main subtypes: anti-glomerular basement membrane (anti-GBM) disease, immune complex-mediated disease, and pauci-immune disease. 1

Diagnosis

Clinical Presentation: Typically presents with nephritic syndrome (hematuria, proteinuria, hypertension, and renal failure).

Laboratory Tests: Elevated serum creatinine (median 3.4 mg/dL) and reduced glomerular filtration rate (median 18 mL/min/1.73m2).

Serological Markers: ANCA positivity in 60.5% of cases, with myeloperoxidase specificity more common than expected. 1 2

Renal Biopsy: Essential for classification into type 1 (anti-GBM), type 2 (immune complex), or type 3 (pauci-immune) RPGN. 1

Management

Type 1 RPGN (Anti-GBM Disease): High-dose corticosteroids and plasmapheresis, often with cyclophosphamide. 1

Type 2 RPGN (Immune Complex-Mediated): Corticosteroids, possibly with immunosuppressive agents like cyclophosphamide or rituximab depending on severity. 1

Type 3 RPGN (Pauci-Immune): Often treated with corticosteroids and cyclophosphamide, with rituximab considered in refractory cases. 1

Monitoring: Regular assessment of renal function, ANCA titers, and clinical status.

Special Populations

Comorbidities: No specific details provided regarding management adjustments for comorbidities in the given abstracts. 1

Pregnancy, Pediatrics, Elderly: Not addressed in the provided abstracts. 1

Key Recommendations

Renal biopsy is essential for diagnosing and classifying RPGN into its subtypes (anti-GBM, immune complex, pauci-immune). (Evidence: Strong 1)

ANCA testing should be performed in all RPGN patients due to its high prevalence and diagnostic utility. (Evidence: Moderate 1 2)

Treatment should be tailored to the specific subtype of RPGN, with high-dose corticosteroids and plasmapheresis for anti-GBM disease, and corticosteroids with adjunctive immunosuppressive therapy for immune complex and pauci-immune types. (Evidence: Expert opinion 1)

References

1 Aydin Z, Turkmen K, Dede F, Yasar E, Ozturk S, Aydin M et al.. Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group. Clinical and experimental nephrology 2021. link 2 Short AK, Esnault VL, Lockwood CM. ANCA and anti-GBM antibodies in RPGN. Advances in experimental medicine and biology 1993. link

Rapidly progressive glomerulonephritis